SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

vTv Therapeutics Randomizes First Participant in Phase 2a Cadisegliatin Study

vTv Therapeutics said it randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin.

VTVT

Related stories